FDA
-
-
-
-
-
-
-
Tempest Announces Interim Results from Ongoing REDEEM-1 Trial of TPST-2003, Preparing for Potential U.S. Registrational Study in 2026
-
-
-
-
-
-
-
Biodexa enrolls first patients in Phase 3 trial for FAP treatment
-
-
-
-
-
-
-
Tempest Therapeutics (TPST) stock rises on EMA Orphan Drug Designation
-
-
-
-
-
-
-
Tempest Therapeutics (TPST) Announces Plan to Explore Strategic Alternatives to Advance Promising Pipeline of Clinical Oncology Assets and Maximize Stockholder Value
-
-
-
-
-
-
-
Tempest Therapeutics (TPST) Granted FDA Fast Track Designation for Amezalpat
-
-
-
-
-
-
-
Tempest Therapeutics (TPST) PT Lowered to $5 at Piper Sandler
-
-
-
-
-
-
-
Tempest Extends Limited Duration Stockholder Rights Plan
-
323,584 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

